The 25th International Harm Reduction Conference (HR17) was held in Montréal, Canada from 14-17 May 2017.

Conference highlights


Canadian Minister of Health opens HR17 conference amid controversy over overdose deaths.

Conference bulletin

Read our HR17 conference bulletin.

United States

Heroin combined with fentanyl is driving overdose crisis in US.

Drug checking programme

Drug checking reveals high levels of fentanyl contamination in Vancouver street drugs.

Generic hepatitis C treatment

Indonesian buyers club helps people obtain generic hepatitis C treatment.

Prevention of mother-to-child transmission

Combining drug addiction treatment and perinatal HIV prevention leads to good outcomes in Kenya.

Direct-acting antivirals

Hepatitis C virus reinfection is uncommon after being cured with DAAs.

Stimulant overdoses

Overamping is a common problem among people who use stimulants.

Opioid dependence treatment

Hydromorphone works as well as heroin-assisted drug addiction treatment.

aidsmap news from HR17

← First1Next →

Subscribe now

Sign up for our free email news bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Official conference website

Find out more on the International Harm Reduction Conference website.

Visit the conference website >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.